Patricia Kane protocol

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

The Patricia Kane protocol (PK protocol) is an experimental treatment for neurological disease involving intravenous infusion of phospholipids and methylation factors, along with dietary changes and supplements.

It is based on the theory that in diseases Kane classes as those of neurotoxicity (e.g., multiple sclerosis, Parkinson's, Chronic Fatigue Syndrome), toxins destabilize cell membranes leading to dysfunctions in cell signaling and homeostasis and neurodegeneration.

Theory[edit]

She seeks to correct deficiencies of Omega 6 and arachidonic acid in cell membranes and correct the over-expression of very long chain fatty acids.

Protocol[edit]

The protocol is individualized but involves several key components: intravenous infusion of phosphatidylcholine and sodium phenylbutyrate, pushes of glutathione and folinic acid, methylcobalamin injections, and increased intake of essentially fatty acids.

Patricia Kane recommends elimination of all processed foods, especially those containing Omega 6 oils, regular intake of pastured eggs, and a "cell membrane stabilizing drink" consisting of liquid phosphatidylcholine, evening primrose oil, whey protein, and a blend of safflower and flax seed oil in a 4:1 ratio of Omega 6 to Omega 3, and a blend of seeds. She also recommends a low carbohydrate, high fat diet.

Medical applications[edit]

Kane believes her protocol can offer clinical benefit in a range of neurological disorders including ALS, Parkinson's Disease, Multiple Sclerosis, Alzheimer's, Autism, pervasive developmental delay, seizure disorders, Post Stroke, traumatic brain injury, metabolic and genetic abnormalities


Evidence[edit]

There have been no clinical trials of the PK protocol for the treatment of any disease.

Some of the individual components of the protocol have been studied.

Sodium phenylbutyate[edit]

In mouse models of Parkinson's, sodium phenylbutyrate was found to protect the loss of dopaminergic neurons.[1][2][3]

See also[edit]

References[edit]

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586072/
  2. http://www.jbc.org/content/286/17/14941.short
  3. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038113


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history